DIABETES OBESITY & METABOLISM

DIABETES OBESITY & METABOLISM Journal

publication venue for

Do nonglycaemic effects such as weight loss account for HbA1c lowering with efpeglenatide?: Insights from the AMPLITUDE-O trial 2024
Effects of ertugliflozin on uric acid and gout-related outcomes in persons with type 2 diabetes and cardiovascular disease: Post hoc analyses from VERTIS CV 2024
Hypoglycaemia and kidney events in participants with type 2 diabetes and atherosclerotic cardiovascular disease: Observations from the VERTIS CV trial 2024
Effect of albiglutide on cardiovascular outcomes in older adults: A post hoc analysis of a randomized controlled trial. 26:1714-1722. 2024
Cardiovascular and renal outcomes with varying degrees of kidney disease in high-risk people with type 2 diabetes: An epidemiological analysis of data from the AMPLITUDE-O trial 2023
Safety and tolerability of semaglutide across the SUSTAIN and PIONEER phase IIIa clinical trial programmes 2023
Potential for residual cardiovascular risk reduction: Eligibility for icosapent ethyl in the VERTIS CV population with type 2 diabetes and atherosclerotic cardiovascular disease 2023
Body weight loss with oral semaglutide is mediated predominantly by effects other than gastrointestinal adverse events in patients with type 2 diabetes: A post hoc analysis. 25:1130-1135. 2023
Cardiorenal outcomes by indices of liver steatosis and fibrosis in individuals with type 2 diabetes and atherosclerotic cardiovascular disease: Analyses from VERTIS CV, a randomized trial of the sodium-glucose cotransporter-2 inhibitor ertugliflozin. 25:758-766. 2022
Weight management in young adults with type 1 diabetes: The advancing care for type 1 diabetes and obesity network sequential multiple assignment randomized trial pilot results 2022
Cardiorenal outcomes with ertugliflozin assessed according to baseline glucose-lowering agent: An analysis from VERTIS CV 2022
The differential effects of ertugliflozin on glucosuria and natriuresis biomarkers: Prespecified analyses from VERTIS CV. 24:1114-1122. 2022
Alliance of Randomized Trials of Medicine vs Metabolic Surgery in Type 2 Diabetes (ARMMS-T2D): Study rationale, design, and methods 2022
Indirect treatment comparisons: Choosing the right tool for the job 2022
An indirect treatment comparison of the efficacy of semaglutide 1.0 mg versus dulaglutide 3.0 and 4.5 mg 2021
Potential kidney protection with liraglutide and semaglutide: Exploratory mediation analysis 2021
Prototype of an evidence-based tool to aid individualized treatment for type 2 diabetes. 23:1666-1671. 2021
The effects of hydroxychloroquine on insulin sensitivity, insulin clearance and inflammation in insulin-resistant adults: A randomized trial. 23:1252-1261. 2021
Cardiovascular outcomes and safety with linagliptin, a dipeptidyl peptidase-4 inhibitor, compared with the sulphonylurea glimepiride in older people with type 2 diabetes: A subgroup analysis of the randomized CAROLINA trial. 23:569-580. 2020
Development of a hypoglycaemia risk score to identify high-risk individuals with advanced type 2 diabetes in DEVOTE. 22:2248-2256. 2020
Design and baseline characteristics of theAMPLITUDE-Ocardiovascular outcomes trial of efpeglenatide, a weekly glucagon-like peptide-1 receptor agonist. 23:318-323. 2020
Effects of glucagon-like peptide-1 receptor agonists liraglutide and semaglutide on cardiovascular and renal outcomes across body mass index categories in type 2 diabetes: Results of theLEADERandSUSTAIN6 trials. 22:2487-2492. 2020
Efficacy and safety of ertugliflozin in older patients with type 2 diabetes: A pooled analysis of phaseIIIstudies. 22:2276-2286. 2020
Impact of microvascular disease on cardiovascular outcomes in type 2 diabetes: Results from theLEADERandSUSTAIN6 clinical trials. 22:2193-2198. 2020
Cardiovascular and renal outcomes by baseline albuminuria status and renal function: Results from theLEADERrandomized trial. 22:2077-2088. 2020
Evaluating glucose-lowering treatment in older people with diabetes: Lessons from the IMPERIUM trial 2020
Risk of severe hypoglycaemia and its impact in type 2 diabetes inDEVOTE. 22:2241-2247. 2020
The effect of glucagon-like peptide-1 receptor agonists liraglutide and semaglutide on cardiovascular and renal outcomes across baseline blood pressure categories: Analysis of the LEADER and SUSTAIN 6 trials. 22:1690-1695. 2020
Validation of distinct type 2 diabetes clusters and their association with diabetes complications in the DEVOTE, LEADER and SUSTAIN-6 cardiovascular outcomes trials. 22:1537-1547. 2020
Efficacy, safety and cardiovascular outcomes of once-daily oral semaglutide in patients with type 2 diabetes: The PIONEER programme 2020
Body weight management and safety with efpeglenatide in adults without diabetes: A phase II randomized study. 21:2429-2439. 2019
Long-term efficacy and safety of combined insulin and glucagon-like peptide-1 therapy: Evidence from the LEADER trial. 21:2450-2458. 2019
Cardiovascular safety and lower severe hypoglycaemia of insulin degludec versus insulin glargine U100 in patients with type 2 diabetes aged 65 years or older: Results from DEVOTE (DEVOTE 7). 21:1625-1633. 2019
Duration of diabetes and cardiorenal efficacy of liraglutide and semaglutide: A post hoc analysis of the LEADER and SUSTAIN 6 clinical trials. 21:1745-1751. 2019
Lower rates of cardiovascular events and mortality associated with liraglutide use in patients treated with basal insulin: A DEVOTE subanalysis (DEVOTE 10). 21:1437-1444. 2019
Genetic, epigenetic and transcriptional variations at NFATC2IP locus with weight loss in response to diet interventions: The POUNDS Lost Trial. 20:2298-2303. 2018
Basal insulin peglispro increases lipid oxidation, metabolic flexibility, thermogenesis and ketone bodies compared to insulin glargine in subjects with type 1 diabetes mellitus. 20:1193-1201. 2018
Ertugliflozin plus sitagliptin versus either individual agent over 52 weeks in patients with type 2 diabetes mellitus inadequately controlled with metformin: The VERTIS FACTORIAL randomized trial. 20:1111-1120. 2018
Glycaemic outcomes of an Individualized treatMent aPproach for oldER vulnerable patIents: A randomized, controlled stUdy in type 2 diabetes Mellitus (IMPERIUM). 20:148-156. 2018
A role for exercise after bariatric surgery? 2016
Efficacy and safety of initial combination therapy with alogliptin plus metformin versus either as monotherapy in drug-naive patients with type 2 diabetes: a randomized, double-blind, 6-month study. 16:613-621. 2014
Effect of pioglitazone on body composition and bone density in subjects with prediabetes in the ACT NOW trial. 15:931-937. 2013
Combination therapy with naltrexone and bupropion for obesity reduces total and visceral adiposity. 15:863-866. 2013
Cardiovascular safety of the dipetidyl peptidase-4 inhibitor alogliptin in type 2 diabetes mellitus. 15:668-673. 2013
Efficacy and tolerability of taspoglutide versus pioglitazone in subjects with type 2 diabetes uncontrolled with sulphonylurea or sulphonylurea-metformin therapy: a randomized, double-blind study (T-emerge 6). 15:234-240. 2013
Comparison of vildagliptin and thiazolidinedione as add-on therapy in patients inadequately controlled with metformin: results of the GALIANT trial - a primary care, type 2 diabetes study. 11:978-986. 2009
Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin in patients with type 2 diabetes inadequately controlled by glyburide monotherapy. 11:167-176. 2009
Robust improvements in fasting and prandial measures of beta-cell function with vildagliptin in drug-naive patients: analysis of pooled vildagliptin monotherapy database. 10:931-938. 2008

category

ENDOCRINOLOGY & METABOLISM Web of Science Category

International Standard Serial Number (ISSN)

1462-8902

Electronic International Standard Serial Number (EISSN)

1463-1326

journal abbreviation

DIABETES OBES METAB